Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Non-Current Assets: 2019-2025

Historic Non-Current Assets for Allogene Therapeutics (ALLO) over the last 7 years, with Sep 2025 value amounting to $179.1 million.

  • Allogene Therapeutics' Non-Current Assets fell 37.11% to $179.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $179.1 million, marking a year-over-year decrease of 37.11%. This contributed to the annual value of $245.3 million for FY2024, which is 33.53% up from last year.
  • As of Q3 2025, Allogene Therapeutics' Non-Current Assets stood at $179.1 million, which was down 4.73% from $187.9 million recorded in Q2 2025.
  • In the past 5 years, Allogene Therapeutics' Non-Current Assets ranged from a high of $579.5 million in Q4 2021 and a low of $179.1 million during Q3 2025.
  • Its 3-year average for Non-Current Assets is $223.4 million, with a median of $216.4 million in 2025.
  • Per our database at Business Quant, Allogene Therapeutics' Non-Current Assets skyrocketed by 151.47% in 2021 and then slumped by 49.48% in 2022.
  • Allogene Therapeutics' Non-Current Assets (Quarterly) stood at $579.5 million in 2021, then crashed by 49.48% to $292.8 million in 2022, then crashed by 37.24% to $183.7 million in 2023, then soared by 33.53% to $245.3 million in 2024, then slumped by 37.11% to $179.1 million in 2025.
  • Its Non-Current Assets stands at $179.1 million for Q3 2025, versus $187.9 million for Q2 2025 and $216.4 million for Q1 2025.